Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients
Brown J, Davids M, Rodon J et al.
Key Points:
PI3Kγ, PI3Kα may be involved in CLL/NHL and inhibition of PI3K signaling.
Investigated impact of SAR245408 on safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effect in patients with relapsed/refractory CLL and NHL.
4/25 patients with CLL had partial response (PR), 1 had nodal PR, and 5 had stable disease (SD).
Majority of patients reported at least grade 3 AEs, with most common including neutropenia, diarrhea, anemia and hypotension.
Implications:
- in conclusion SAR245408 monotherapy demonstrated clinical activity in patients with relapsed or refractory CLL and promising pharmacodynamic effects on chemokine levels.
View the original abstract on the ASH website.
